Starting February 1, 2027, Ontario's Assistive Devices Program will no longer require applicants to use insulin injections for one year before receiving pump funding, and grant renewals will move from every year to every two years, the Sydenham Current reported. The program fully funds approved pumps and pays $2,400 a year for supplies. In 2025-26 it spent about $95 million on pumps and supplies for nearly 24,000 people. The province announced the change ahead of World Diabetes Day.
The Edmonton Diabetes and High Risk Foot Clinic now lets Albertans with type 1 diabetes book an insulin pump consultation directly, starting with a phone call with a nurse practitioner, Global News reported. The clinic says it has no waitlist and most patients can be on a pump in about two months, compared with waits of up to two years elsewhere. Alberta's health ministry said more than 7,000 people used the province's funded pump program in 2025-26, up from about 4,000 in 2021-22.
Sandoz Group AG's preparations for a Q3 2026 Canadian commercial launch of generic semaglutide came into sharper focus over the weekend as Health Canada continues reviewing seven remaining generic submissions filed after the April 28 Dr. Reddy's and May 1 Apotex approvals. Sandoz signaled in late 2024 it would launch a Canadian generic semaglutide in 2026 when the active-drug patent expired; the company's filing is currently under Health Canada review with commercial readiness contingent on the agency's review timeline. Industry analysts expect Sandoz to enter the Canadian market with pricing 45-90% below the brand Ozempic CAD $300-400/month range, putting Sandoz generic pricing in the CAD $30-200/month tier (~$22-145 USD/month). The Canadian generic market is a five-year preview of what will hit the US after December 2031 patent expiry; watch what Ontario, BC, and Quebec formulary committees decide on listing terms over the next 90 days.